Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Jun 19;7:3811. doi: 10.1038/s41598-017-03798-3

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2017

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Immunogenicity of nanoparticle vaccines. (A) Anti-Pfs25 IgG titers measured by ELISA in mice (n = 10) vaccinated twice with doses corresponding to 1 μg Pfs25 per immunisation in Alhydrogel® at three weeks post prime (left panel) and three weeks post boost (right panel). (B) Avidity of serum IgG responses was assessed by NaSCN-displacement ELISA and is reported as the reduction in OD by incubation with varying concentrations of NaSCN compared to incubation with PBS (left panel). Lines represent the arithmetic mean of the combined data from each mouse within the group. EC50 (concentration of NaSCN required to reduce the OD405 to 50% of that without NaSCN) was then determined using a sigmoidal dose response (variable slope) regression (right panel). ns p > 0.05, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001.